Irinotecan is a topoisomerase I interactive agent, widely used in the treatment of metastatic colorectal cancer. The genotoxic effects of the maximum single dose (18 µg mL -1 ), recommended monotherapy dose (9 µg mL -1 ), and recommended combined therapy dose (4.5 µg mL -1
Irinotecan is a semi-synthetic derivative of camptothecin, a quinoline-based alkaloid and DNA topoisomerase I inhibitor (1, 2) . It inhibits DNA cleavage and re-ligation induced by topoisomerase I (3, 4) . Normally, it is prescribed only for colorectal cancer cases that have not responded to standard chemotherapy with 5-fl uorouracil.
As an approved anticancer agent, irinotecan damages the DNA molecule indirectly, by inhibiting enzymes which modulate DNA topology. Irinotecan stops the growth of cancer cells by preventing the development of elements necessary for cell division, i.e. it keeps the chromosomes wound tight, so the cell cannot make proteins, and as a result, cells stop growing (5) .
Topoisomerases are enzymes that produce reversible single-strand breaks in the DNA during replication. These enzymes wind and unwind the DNA that makes up chromosomes. Irinotecan binds to the topoisomerase I DNA complex and prevents religation of the DNA strand, which leads to double-strand DNA breakage and cell death (6) .
Irinotecan is S-phase cell cycle specifi c (1, 7, 8) . Li and co-workers (9) found that cells in the S-phase were 100 to 1,000 times more sensitive to camptothecin in vitro than cells in G 1 or G 2 . Irinotecan proved clastogenic in the mammalian in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronucleus test in mice) test systems (10) .
Here we studied the genotoxic effects of the maximum single dose of 18 µg mL -1 , recommended monotherapy dose of 9 µg mL -1 , and recommended combined therapy dose of 4.5 µg mL -1 of irinotecan on cultured V79 cells using the alkaline comet assay, cytochalasin B blocked micronucleus assay, and the chromosome aberration assay.
We investigated whether this drug was genotoxic to the cells in the applied doses, and how time of exposure infl uenced the results.
MATERIAL AND METHODS

Reagents
Irinotecan (Campto ® ) was purchased from Aventis Pharma Ltd. It was used in the form of irinotecan hydrochloride trihydrate as a 5 mL sterile solution for infusion (at the concentration of 20 mg mL -1 ). A stock solution for the study was prepared with sterile redistilled water. The fi nal concentrations used in our in vitro experiment were: 18 µg mL -1 , 9 µg mL -1 , and 4.5 µg mL -1 , corresponding to respective maximal single dose of 700 mg m -2 , recommended monotherapy dose of 350 mg m -2 , and recommended combined therapy dose of 180 mg m -2 . Mitomycin C (MMC) was purchased from Sigma (St. Louis, MO, USA).
Cell culture
Chinese hamster V79 cell line was cultured as a monolayer in an F-10 medium (Sigma) supplemented with 20 % calf serum, penicillin (100 IU mL -1 ), and streptomycin (100 µg mL -1 ). Cells, whose passage number was below 20, were maintained at 37 °C in a humidifi ed atmosphere containing 5 % CO 2 . For the experiment, the cells were seeded at 1.5 x 10 4 cells mL -1 to 2.0 x 10 4 cells mL -1
. After a 24-h growth, the culture was treated with irinotecan for 2 h and 24 h, and then washed twice with cold phosphate buffered saline (PBS), followed by incubation for an additional 24 h in a fresh medium. Its genotoxic effect was studied for three doses: 4.5 µg mL -1 , 9 µg mL -1 , and 18 µg mL -1 . MMC (0.5 µg mL -1 ) was used as positive control. Untreated control was also included in the experiment.
Alkaline comet assay
The alkaline version of the comet assay was performed according to the method of Singh et al. (11) with minor modifi cations. Fully frosted microscope slides (Surghipath, Richmond, IL, USA) were precoated with 1 % of normal melting point agarose (NMP) (Sigma). After solidifi cation, this layer was removed. 300 µL of 0.6 % NMA was pipetted onto the slides, covered with a cover slip, and placed on a metal tray over ice for 10 min to solidify. Cell suspensions of V79 hamster cells were mixed with 100 µL of 0.5 % low melting point (LMP) agarose (Sigma), pipetted over the 0.6 % NMP agarose, and placed on ice for 10 minutes to solidify. 0.5 % LMP was used as the fi nal protective layer. Slides were placed overnight in a cold lysis solution containing 2.5 mol L -1 NaCl, 100 mmol L -1 Na 2 EDTA, 10 mmol L -1 Tris, pH 10, and 1 % sodium N-lauroylsarcosinate to which 10 % of dimethylsulphoxide (DMSO) and 1 % Triton X-100 have been added just before use. After the lysis, the slides were placed in an electrophoresis buffer (300 mmol L -1 NaOH and 1 mmol L -1 Na 2 EDTA, pH13) for 20 min to allow for unwinding of the DNA. Electrophoresis was conducted in the same buffer by applying an electric current of 300 mA, at 25 V for 20 min using a horizontal electrophoresis power tank (Life Technologies, Gaithersburg, MD, USA). Finally, the slides were washed three times for fi ve minutes with a neutralisation buffer (0.4 mol L -1 Tris, pH 7.5) and stained with ethidium bromide (20 µg mL -1 , Sigma). All steps of the comet assay preceding electrophoresis were performed on ice to prevent DNA repair and effects of metabolic processes. Furthermore, to avoid position effects during electrophoresis, two parallel replicate slides per sample were prepared, and each replicate was processed in a different electrophoretic run.
Image analysis was performed using an automatic digital analysis system (Comet Assay II, Perceptive Instruments Ltd., Suffolk, Halstead, UK) fi tted with Leitz Orthoplan fl uorescence microscope equipped with an excitation fi lter of 515 nm to 560 nm.
Nuclei were excited with green light, and the emitted red spectrum was captured by a 25x immersion objective. Images of 100 randomly selected nuclei were analysed per sample. Experiments were carried out in triplicate. The tail length, the length of migration starting from the leading edge of the head, and the tail moment were selected as sensitive indicators of genotoxicity.
Cytochalasin B-blocked micronucleus test
Duplicate cultures were seeded in a Lab-Tek II Chamber Slide W/Cover (Nagle Nunc International, Naperville, IL, USA) and maintained in an incubator at +37 °C in humifi ed atmosphere containing 5 % CO 2 for 24 h before treatment.
In the 2-h treatment, the medium was removed, cells washed twice with PBS, fresh medium with cytochalasin B (Sigma) (in 0.6 µg mL -1 final concentration) was added, and cultivation continued for another 24 h. In the 24-h treatment, irinotecan and cytochalasin B (Sigma) (in 0.6 µg mL -1 final concentration) were added 24 h after seeding, and cultivation was continued for another 24 h.
At the end of the incubation period, the medium was removed, cells washed twice with PBS, trypsinised, resolved in complete medium and centrifuged, swollen in 0.075 mol L -1 KCl, fi xed in methanol:acetic acid (5:1), spread on slides, air-dried, and stained with 5 % Giemsa stain (Merck, Darmstadt, Germany). Two thousand binucleated cells with well preserved cytoplasm were analysed for each irinotecan dose (1000 binucleated cells for each parallel culture).
Chromosome aberration assay
Triplicate cultures were seeded in Lab-Tek II Chamber Slide W/Cover (Nagle Nunc International, Naperville, IL, USA) as described above. After a 24-h growth, the cultures were treated with irinotecan and incubated for 2 h and 24 h. In the 2-h treatment, the medium was removed; cells washed twice with PBS, and incubated with a fresh F-10 medium for another 22 h. In the 24-h treatment, the drug was left in the cultures until harvesting. Colchicine (Sigma) was added two hours before harvesting to arrest cells in metaphase. At the end of the incubation period, the medium was removed; cells washed twice with PBS, trypsinised, resolved in complete medium and centrifuged, swollen in 0.075 mol L -1 KCl, fi xed in methanol: acetic acid (3:1), spread on slides, airdried, and stained with 5 % Giemsa stain. Six hundred metaphases per irinotecan dose (200 metaphases per parallel culture) were analysed.
Statistical analysis
For the comet assay and micronucleus test, data were analysed using one-way analysis of variance (ANOVA) for multiple comparisons. Tukey post hoc test was used to examine the differences between samples. A probability level of P<0.05 was considered to be signifi cant. The nonparametric Mann-Whitney U test was performed to analyse chromosome aberrations.
RESULTS
The alkaline comet assay
The lengths and shapes of the comets refl ect the amount of DNA fragmentation. Table 1 shows the results of the alkaline comet assay for 2-h and 24-h exposure to irinotecan. The ANOVA test did not show signifi cant differences between the exposed and control samples either in the tail length or tail moment. However the tail length differed signifi cantly between positive and negative control (P=0.0479) for the 2-h exposure.
After 24-h exposure, there was a significant difference in the tail length and tail moment between samples treated with 9 µg mL -1 of irinotecan and either control. Positive control samples signifi cantly differed in both parameters from samples treated with 18 µg mL -1 , and 4.5 µg mL -1 of irinotecan, while from samples treated with 9 µg mL -1 of irinotecan they signifi cantly differed only in the tail moment. The difference was also signifi cant in the tail length and tail moment between all three irinotecan-treated groups.
Micronucleus assay
The results of the micronucleus (MN) frequency test are presented in Table 2 . After 2 h of exposure to irinotecan, all irinotecan-treated samples had a signifi cantly higher micronucleus frequency than negative or positive control samples. Samples treated with 4.5 µg mL -1 had a significantly lower MN frequency than samples treated with 18 µg mL -1 or 9 µg mL -1 of irinotecan. These differences were not dose-dependent.
After the 24-h exposure, positive control samples and 9 µg mL -1 of irinotecan showed a significant increase compared to the negative control. Signifi cant difference was observed between positive control and 4.5 µg mL -1 of irinotecan. The sample treated with 18 µg mL -1 of irinotecan could not be analysed due to low number of surviving cells. Table 3 shows the results of the chromosome aberration analysis. In 2-h treatment, dicentric chromosomes increased with the dose of irinotecan, but the increase was not statistically significant. The nonparametric Mann-Whitney U test showed signifi cant differences in acentric fragments between irinotecan doses of 18 µg mL -1 and 4.5 µg mL -1 (P< 0.05). We also observed signifi cant differences in tetraploidy between the sample treated with 4.5 µg mL -1 of irinotecan and positive control (P<0.05), and between samples treated with 4.5 µg mL -1 and 9 µg mL -1 of irinotecan (P<0.05). After the 24-h treatment, only the effects of the lowest concentration of irinotecan (4.5 µg mL -1 ) could be analysed. The number of surviving cells in other sample groups was not suffi cient for statistical analysis (Table 3) .
Chromosome aberration analysis
DISCUSSION
In this study we evaluated the cytotoxic and genotoxic effects of three therapeutically relevant doses of irinotecan (Campto ® ) on V79 cells, following 2 h and 24 h of exposure in vitro. The choice of a prolonged exposure was based on previous reports on the mechanism of cytotoxicity of camptothecin analogues (12) .
To get a better insight into the nature of intracellular damage caused by the treatment, we used the alkaline comet assay, cytochalasin B blocked micronucleus assay, and chromosome aberration analysis.
These endpoints showed that irinotecan simultaneously induced primary DNA damage, structural chromosome aberrations, and mitotic spindle damage in treated cells.
The alkaline comet assay did not show statistically signifi cant differences either in the tail length or tail moment between samples treated with irinotecan for two hours. The 24-hour exposure did however yield signifi cant differences, which were not dose-or timedependent. Curiously enough, we found more DNA damage with irinotecan dose of 9 µg mL -1 than with 18 µg mL -1 . This may be because highly fragmented DNA from cells treated with the latter dose is not captured on microgel. Camptothecin causes singlestrand breaks in DNA, but the breaks are rapidly repaired after drug removal, while the cytotoxic action of camptothecin is sustained (13). Kopjar et. al. (14) , tested the toxicity of 4.6 µg mL -1 and 9 µg mL -1 irinotecan on human blood cells, and also reported higher cytotoxicity at a lower dose of the drug. The other possible explanation for our results could be the apoptotic elimination of cells whose DNA was not repaired.
Recent studies have shown that camptothecin and its analogues can strongly induce apoptosis in different types of cells (13, 15, 16) . Literature shows that irinotecan-induced changes in gene expression profi les in vitro and in vivo are consistent with the temporary delay in G 1 -S transition and with enhanced responsiveness to apoptosis, both of which may contribute to the synergistic interactions between this drug and antimetabolites (17) . In a study by Ohyama et al. (18) , irinotecan induced apoptosis of SW-620 cells by increasing the poly(ADP-ribose) polymerase (PARP) cleavage (to 60 % vs. 7 % basal level). Gibson et al. (19, 20) reported increased apoptosis in the intestines of breast cancer-bearing dark agouti rats after treatment with irinotecan. Daza et al. (21) described DNA strand breaks in G 0 human leukocytes after one-hour exposure to irinotecan, that were repaired 24 h after exposure.
Godard et al. (22) found that the comet assay was able to detect stabilised cleavable complexes and apoptosis induced by camptothecin. DNA strand breaks were present after one hour of treatment, and disappeared within 24 h after drug removal from Chinese hamster ovary (CHO) cells, DC3F cells, and DC3F/C-10 cells. Kinetics studies allowed to discriminate between these early DNA damages and DNA fragmentation related to apoptosis characterised by the reappearance of DNA strand breaks 48 h after treatment (22) . Other studies on animal and human cell lines confi rm the ability of camptothecin to cause high primary DNA damage, mainly in the form of singleand double-strand breaks. Gradzka et al. (23) suggest that a higher initial rate of repair of replication-related double-strand breaks may contribute to the relative camptothecin resistance of murine lymphoma cells.
Ollikainen et al. (24) found a slight increase in DNA single-strand breaks in human mesothelioma cells (M14K and M25K) induced by SN-38 (an active metabolite of irinotecan) at a concentration of 10 -8 mmol L -1 . Chromosome damage caused by exposure to irinotecan has also been described. Anderson and Berger (25) showed that irinotecan induced sister chromatid exchanges, chromosomal aberrations, and mutations in specifi c mammalian genes. Voight et al. (26) observed chromatid breaks associated with radial chromosome configurations and sister chromatid exchanges after 24 h of exposure to irinotecan. However, near maximum clastogenic effects were evident immediately after a 2-h drug exposure.
In our study, we analysed for chromosome aberrations only those samples that were exposed to irinotecan for two hours because prolonged exposure would completely block cell proliferation and no metaphases would be obtained. Treatment with irinotecan signifi cantly affected the frequency of acentric fragments. Although a four-fold increase was found for dicentric chromosomes at the dose of 18 µg mL -1 of irinotecan compared to other applied doses, the result was not signifi cant. In addition, we found a signifi cant increase in the frequency of tetraploidy in the treated samples.
All these results are consistent with previous reports, which indicate that cell sensitivity to camptothecin is the highest during their progression through the S phase, and that the drug delays the cell cycle traverse in the S/G 2 phase (27, 28) .
The ability of camptothecin to induce MN was confirmed both on transgenic (29) and nontransgenic mice (30, 31) . In their in vivo clastogenicity study, Hardman et al. (32) reported that irinotecan significantly elevated MN frequency in mouse peripheral blood erythrocytes. Aydemir and Bilaloglu (33) found an increase in MN frequency in the bone marrow cells of mice treated with topotecan (an analogue of irinotecan). Kopjar et al. (14) found a signifi cant increase in the MN frequency in human lymphocytes even at a lower dose of 4.6 µg mL -1 of irinotecan.
The best explanation of the nature of damage caused by irinotecan was provided by Attia et al. (34) . By combining the micronucleus test with fl uorescence in situ hybridisation (FISH) using a mouse minor satellite DNA probe they distinguished MN of clastogenic and aneugenic origin and found that irinotecan was genotoxic and produced chromosomal damage that ended up as MN.
CONCLUSIONS
Our findings indicate that therapeutic doses of irinotecan are genotoxic to V79 cells, but the effect is neither dose-nor time-dependent under the experimental conditions. A two-hour exposure to irinotecan did not cause DNA single-strand breaks in V79 cells at applied concentrations, while a twentyfour-hour exposure resulted in DNA single-strand breaks regardless of the concentration. Chromosome aberration analysis confi rmed the clastogenic effects of the drug and showed its potential to block cell division after 24 h of exposure. This study has singled out the micronucleus assay as the most reliable method for sensitive detection of cellular damage caused by irinotecan. Although no dose-or time-dependent effect was observed, this test provided the most consistent results, since both treatments resulted in increased MN frequency compared to control samples.
Regardless of the limitations of in vitro studies, their results could help to predict the outcome of therapies with antineoplastic drugs. Based on previous reports and our own results, we can conclude that the further studies are needed to shed more light on the mechanisms of genotoxic action of irinotecan at the cell level.
Sažetak
PROCJENA CITO-/GENOTOKSIČNOSTI IRINOTEKANA U V79-STANICAMA PRIMJENOM KOMET-TESTA, MIKRONUKLEUS-TESTA I TESTA KROMOSOMSKIH ABERACIJA Irinotekan je citotoksični lijek koji inhibira enzim DNA-topoizomerazu I. U širokoj je primjeni u terapiji metastatskog karcinoma kolona i rektuma. U uvjetima in vitro primjenom komet-testa, analize kromosomskih aberacija i mikronukleus-testa na V79-stanicama istražili smo genotoksični učinak maksimalne pojedinačne doze (18 µg mL -1 ), preporučene monoterapijske doze (9 µg mL -1 ) i preporučene doze irinotekana za kombiniranu terapiju (4,5 µg mL -1 ). Kulture stanica bile su tretirane irinotekanom 2 h i 24 h. Statistička značajnost određivana je jednosmjernim ANOVA-testom i neparametrijskim Mann Whitneyevim U-testom. Komet-testom nije utvrđen učinak koncentracije i/ili vremena izloženosti. Analiza kromosomskih aberacija pokazala je prisutnost izmjena kromatida, tj. porast broja triradijusa i tetraradijusa. Iako je u kulturama stanica izloženim irinotekanu opažen značajan porast broja mikronukleusa u odnosu na kontrolu, nije uočena ovisnost o dozi lijeka ni o vremenu izloženosti u opisanim eksperimentalnim uvjetima. Dobiveni rezultati upućuju na genotoksičnost irinotekana za V79-stanice. Nijednom od primijenjenih metoda nije utvrđena ovisnost učinka irinotekana o vremenu ili dozi. 
